Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Bryan Johnson, who’s spending hundreds of millions of dollars on treatments designed to extend his life, is many things to ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...